Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Other Non-Current Liabilities (2016 - 2025)

Sanofi's Other Non-Current Liabilities history spans 9 years, with the latest figure at $7.8 billion for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 9.81% year-over-year to $7.8 billion; the TTM value through Dec 2025 reached $7.8 billion, down 9.81%, while the annual FY2025 figure was $7.6 billion, 13.57% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $7.8 billion at Sanofi, down from $8.7 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $8.7 billion in Q4 2024 and bottomed at $1.3 billion in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $7.8 billion (2025), against an average of $5.4 billion.
  • The largest annual shift saw Other Non-Current Liabilities fell 28.44% in 2021 before it surged 550.2% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.3 billion in 2021, then dropped by 1.64% to $1.3 billion in 2022, then soared by 550.2% to $8.2 billion in 2023, then increased by 5.77% to $8.7 billion in 2024, then fell by 9.81% to $7.8 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Other Non-Current Liabilities are $7.8 billion (Q4 2025), $8.7 billion (Q4 2024), and $8.2 billion (Q4 2023).